How to Help Your Patients Save Money on Tymlos: A Provider's Guide to Savings Programs

Tymlos (abaloparatide) has a list price exceeding $4,000 per month — and over an 18- to 24-month treatment course, that translates to $72,000–$100,000 before any financial assistance. For many patients, cost is not just a concern; it's the primary reason they never start or stay on treatment.

As a prescriber, knowing and actively discussing savings options can be the difference between a patient completing their course of therapy and one who abandons it after the first copay shock. This guide walks through every Tymlos savings program available in 2026, with practical guidance on how to enroll patients and address common financial barriers.

Program 1: Tymlos Savings Card (Commercially Insured Patients)

The Tymlos Savings Card from Radius Health / Ipsen is the single most impactful intervention for commercially insured patients. Eligible patients may pay as little as $0 per month. This can transform a $400–$800 monthly copay into nothing — a compelling reason to discuss this program proactively at the time of prescribing.

Key program details:

Eligible patients: Those with commercial (private) insurance covering Tymlos. Excludes Medicare, Medicaid, and government-funded plans.

Maximum benefit: Annual cap applies; details available through the program. Once the cap is reached, patients pay remaining out-of-pocket costs.

How to enroll: Patients (or your office) can enroll via phone (1-855-243-6222) or online at tymloshcp.com/access-and-savings. Enrollment can happen before the prescription is filled.

Dispense at specialty pharmacy: The savings card is applied at the time of dispensing. The specialty pharmacy should have the program information on file.

Office workflow tip: Build savings card enrollment into your Tymlos prescribing workflow. Train your medical assistant or care coordinator to ask every new Tymlos patient about their insurance type and initiate enrollment at checkout. This removes a barrier patients might not navigate on their own.

Program 2: Radius Assist Patient Assistance Program

For patients who are uninsured or underinsured, the Radius Assist program (also called Together with Tymlos) can provide Tymlos at no cost to qualifying patients. This program is income-based and has eligibility criteria that may change annually.

Program parameters:

Duration: Up to 24 months maximum (aligned with the 2-year Tymlos lifetime limit)

Prescriber involvement: Required. Your office will need to sign off on the application and provide clinical documentation.

Application: Phone: 1-866-896-5674; Web: tymloshcp.com/access-and-savings

Re-verification: Patients may need to re-verify eligibility annually. Changes to criteria affect new applicants and re-verifications.

Supporting Medicare Patients: Part D Strategies

Medicare patients face a different landscape. They cannot use the manufacturer's savings card (by federal law), and Tymlos is typically placed on Tier 5 (specialty tier) with coinsurance rates that can still result in significant out-of-pocket costs. Here's how to help:

Part D out-of-pocket cap: The 2026 Medicare Part D annual out-of-pocket cap is $2,100. Once reached, the plan covers 100% of covered drugs for the rest of the year. For high-cost drugs like Tymlos, patients often reach this cap within the first 1–2 months of the year.

Extra Help / Low Income Subsidy (LIS): Screen patients for LIS eligibility. Patients who qualify pay significantly reduced Part D costs across all tiers. Screen using the Social Security Administration's online tool or by calling 1-800-MEDICARE.

Medicare Prescription Payment Plan: Available since January 2025, this allows Medicare Part D enrollees to spread out-of-pocket drug costs across the year rather than paying large lump sums upfront. Recommend this to patients who face cost anxiety at prescription pickup.

Annual plan review: During Medicare Open Enrollment (October 15–December 7), encourage patients to review plans and select one that covers Tymlos at the lowest coinsurance. Plan comparison tools at Medicare.gov can filter by drug coverage.

Discussing Cost With Your Patients: A Clinical Communication Framework

Cost is one of the top reasons patients abandon specialty medications before completing treatment. Proactive communication at the time of prescribing reduces abandonment rates significantly. A simple framework:

Acknowledge the cost upfront: 'Tymlos is expensive without assistance — but I want to make sure we have a plan so cost isn't a barrier for you.'

Identify insurance type: Commercial → savings card; no insurance → patient assistance program; Medicare → Part D strategies and LIS screening.

Start enrollment at the appointment: Don't send patients home to figure this out themselves. Use Together with Tymlos hub services (1-866-896-5674) to initiate enrollment while the patient is still in your office or immediately after.

Follow up at first refill: Check in with the patient at their next appointment about any cost issues. Abandonment risk is highest after the first fill, when the savings card annual cap may not yet have kicked in or when PA delays cause stress.

When to Consider Switching to a More Affordable Alternative

If a patient has exhausted all savings options and cost remains prohibitive, consider whether a different anabolic agent might be accessible:

Generic teriparatide (Teva, Alvogen): Comparable mechanism of action; as low as ~$1,146/month with GoodRx coupons. Broader formulary placement.

Romosozumab (Evenity): May be covered at a different formulary tier; 12-month course. Contraindicated in cardiovascular risk patients.

Bisphosphonates: For patients at moderate risk or as sequential therapy, generic alendronate at ~$10–$30/month is highly accessible.

Use medfinder to Help Patients Find Tymlos After Savings Are Arranged

Once cost barriers are addressed, the final hurdle is locating a specialty pharmacy that has Tymlos in stock and can fill within the patient's preferred timeline. medfinder for providers calls pharmacies near the patient to check availability and texts results to the patient directly — removing the pharmacy-hunting burden from both patient and clinical staff.

For a broader overview of access barriers and prior authorization strategies, see our full guide on Tymlos access issues for providers in 2026.